Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load

Study acronym: EASIER
StatusCompleted
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv10
  2. Publications: 3 to 9v9
  3. Interventions: Enfuvirtide (Drug), Raltegravir (Drug) to FTC/TDF + EFV or LPV/R (Drug), FTC/TDF + EFV or LPV/R +T20 (Drug)
    • Secondary endpoints revised (10)
    • Study arms: 0 to 2
    v8
  4. Trial status: Active, Not Recruiting to Completed
    • Start date: Apr 2007 to May 2007
    v7
  5. Primary and study completion dates: Sep 2008v6
Show 4 earlier versionsHide 4 earlier versions
  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  4. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Switching from enfuvirtide to raltegravir in the treatment of HIV-infected patients who sustain viral suppression with a combination therapy including enfuvirtide (or : with an enfuvirtide-based combination therapy)
Trial Details
NCT Number NCT00454337
Lead Sponsor French National Agency for Research on AIDS and Viral Hepatitis
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 HIV Infections
Related terms HIV Infections
Enrollment 170 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov